{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:21:21Z","timestamp":1792725681097,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008233","name":"School of Medicine, Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["TMSZ-2020-205"],"award-info":[{"award-number":["TMSZ-2020-205"]}],"id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To retrospectively analyze the clinical characteristics of patients undergoing surgical treatment for gastrointestinal stromal tumors (GISTs) in Ruijin Hospital and explore the relevant prognosis clinical factors after surgical treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We screened out 1015 patients with GISTs diagnosed and treated during January 2010 to December 2019. We performed univariate analysis by the log-rank test and multivariate analysis by COX regression. The Kaplan\u2013Meier method was used to estimate the disease-free survival (DFS) and overall survival (OS) of the whole group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All 1015 patients in the whole group received radical surgery, and the proportion of patients with high, intermediate, and low risk was 31.1%, 21.7%, and 47.3%, respectively. Among the 480 low-risk patients, surgery could achieve radical therapy; only the Ki-67 index was related to DFS and OS (DFS: <jats:italic>p<\/jats:italic>\u2009=\u20090.032, OS: <jats:italic>p<\/jats:italic>\u2009=\u20090.009) among the 140 intermediate-risk patients with tumors located in the stomach, whether received Tyrosine kinase inhibitors (TKIs) therapy did not affect the prognosis of patients (DFS: <jats:italic>p<\/jats:italic>\u2009=\u20090.716, OS: <jats:italic>p<\/jats:italic>\u2009=\u20090.848). Among the 331 high-risk patients, those with non-gastric tumors (those outside the stomach, duodenum, and small intestine, HR 1.55, 95% CI 1.19\u20132.00, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), tumor diameter\u2009&gt;\u200910\u00a0cm (hazard ratio, HR 2.63, 95% confidence interval, CI 2.09\u20134.03, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), as well as high-risk patients with mitotic rate\u2009&gt;\u200910\/50 HPF (HR 2.74, 95% CI 2.00\u20133.76, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), the overall prognosis was obviously worse than that of other patients. For some high-risk patients, prolonged postoperative imatinib therapy could significantly improve the survival of patients (HR 0.43, 95% CI 0.15\u20130.66, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For the vast majority of GIST patients, surgery can be curative; but in intermediate-risk patients, the Ki-67 index and postoperative TKI treatment are closely related to prognosis. For intermediate-risk patients whose primary tumor is the stomach, the value of TKI-targeted therapy after surgery seem be not necessary in our study. However, for some high-risk patients, the prognosis of patients can be improved by appropriately prolonging the treatment time of TKI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-023-02897-y","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T10:03:08Z","timestamp":1674468188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical characteristics and outcomes of gastrointestinal stromal tumor patients receiving surgery with or without TKI therapy: a retrospective real-world study"],"prefix":"10.1186","volume":"21","author":[{"given":"Lingquan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhentian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"2897_CR1","first-page":"889","volume":"13","author":"A El-Menyar","year":"2017","unstructured":"El-Menyar A, Mekkodathil A, Al-Thani H. Diagnosis and management of gastrointestinal stromal tumors: an up-to-date literature review. J Cancer Res Ther. 2017;13:889\u2013900.","journal-title":"J Cancer Res Ther"},{"key":"2897_CR2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/j.1582-4934.2006.tb00541.x","volume":"10","author":"KW Min","year":"2006","unstructured":"Min KW, Leabu M. Interstitial cells of Cajal (ICC) and gastrointestinal stromal tumor (GIST): facts, speculations, and myths. J Cell Mol Med. 2006;10:995\u20131013.","journal-title":"J Cell Mol Med"},{"key":"2897_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-med-043010-091813","volume":"63","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med. 2012;63:247\u201358.","journal-title":"Annu Rev Med"},{"key":"2897_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12029-018-0115-2","volume":"50","author":"LS Lino-Silva","year":"2019","unstructured":"Lino-Silva LS, Segales-Rojas P, Aguilar-Cruz E, Salcedo-Hernandez RA, Zepeda-Najar C. Gastrointestinal stromal tumors risk of recurrence stratification by tumor volume is a best predictor compared with risk based on mitosis and tumor size. J Gastrointest Cancer. 2019;50:513\u20138.","journal-title":"J Gastrointest Cancer"},{"key":"2897_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/000313481207800139","volume":"78","author":"D Han","year":"2012","unstructured":"Han D, Deneve J, Gonzalez RJ. Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters. The consequences of tumor rupture. Am Surg. 2012;78:74\u20139.","journal-title":"Am Surg"},{"issue":"Suppl 5","key":"2897_CR6","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0959-8049(02)80601-3","volume":"38","author":"PJ Roberts","year":"2002","unstructured":"Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38(Suppl 5):S37-38.","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"2897_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","volume":"8","author":"GD Demetri","year":"2010","unstructured":"Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1-41 quiz S42-44.","journal-title":"J Natl Compr Canc Netw"},{"key":"2897_CR8","first-page":"S0003469X170261","volume":"88","author":"M Ortenzi","year":"2017","unstructured":"Ortenzi M, Ghiselli R, Cardinali L, Guerrieri M. Surgical treatment of gastric stromal tumors: laparoscopic versus open approach. Ann Ital Chir. 2017;88:S0003469X17026112.","journal-title":"Ann Ital Chir"},{"issue":"9","key":"2897_CR9","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.1007\/s00464-022-09014-2","volume":"36","author":"J Gevorkian","year":"2022","unstructured":"Gevorkian J, Le E, Alvarado L, Davis B, Tyroch A, Chiba S, Konstantinidis IT. Trends and outcomes of minimally invasive surgery for gastrointestinal stromal tumors (GIST). Surg Endosc. 2022;36(9):6841\u201350.","journal-title":"Surg Endosc"},{"key":"2897_CR10","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1007\/s00464-019-07284-x","volume":"34","author":"IT Konstantinidis","year":"2020","unstructured":"Konstantinidis IT, Ituarte P, Woo Y, Warner SG, Melstrom K, Kim J, Singh G, et al. Trends and outcomes of robotic surgery for gastrointestinal (GI) cancers in the USA: maintaining perioperative and oncologic safety. Surg Endosc. 2020;34:4932\u201342.","journal-title":"Surg Endosc"},{"key":"2897_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-015-1554-9","volume":"15","author":"U Guller","year":"2015","unstructured":"Guller U, Tarantino I, Cerny T, Schmied BM, Warschkow R. Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor. BMC Cancer. 2015;15:557.","journal-title":"BMC Cancer"},{"key":"2897_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ijsu.2018.03.074","volume":"53","author":"B Badic","year":"2018","unstructured":"Badic B, Gancel CH, Thereaux J, Joumond A, Bail JP, Meunier B, Sulpice L. Surgical and oncological long term outcomes of gastrointestinal stromal tumors (GIST) resection- retrospective cohort study. Int J Surg. 2018;53:257\u201361.","journal-title":"Int J Surg"},{"key":"2897_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/00003495-200363050-00005","volume":"63","author":"KF Croom","year":"2003","unstructured":"Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs. 2003;63:513\u201322 discussion 523-514.","journal-title":"Drugs"},{"key":"2897_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620\u20135.","journal-title":"J Clin Oncol"},{"key":"2897_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, Ramadori G, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265\u201372.","journal-title":"JAMA"},{"key":"2897_CR16","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1200\/JCO.2013.51.2046","volume":"32","author":"CL Corless","year":"2014","unstructured":"Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014;32:1563\u201370.","journal-title":"J Clin Oncol"},{"key":"2897_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","volume":"34","author":"H Joensuu","year":"2016","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34:244\u201350.","journal-title":"J Clin Oncol"},{"key":"2897_CR18","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jamaoncol.2020.2091","volume":"6","author":"H Joensuu","year":"2020","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schutte J, Cameron S, et al. Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up. JAMA Oncol. 2020;6:1241\u20136.","journal-title":"JAMA Oncol"},{"key":"2897_CR19","first-page":"518","volume":"111","author":"PA Clavien","year":"1992","unstructured":"Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111:518\u201326.","journal-title":"Surgery"},{"key":"2897_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1053\/hupa.2002.124123","volume":"33","author":"M Miettinen","year":"2002","unstructured":"Miettinen M, El-Rifai W, L HLS, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478\u201383.","journal-title":"Hum Pathol"},{"key":"2897_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.21147\/j.issn.1000-9604.2017.04.01","volume":"29","author":"J Li","year":"2017","unstructured":"Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y, He Y, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res. 2017;29:281\u201393.","journal-title":"Chin J Cancer Res"},{"key":"2897_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/SLA.0b013e3181cc8f6b","volume":"251","author":"HH Kim","year":"2010","unstructured":"Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report\u2013a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg. 2010;251:417\u201320.","journal-title":"Ann Surg"},{"key":"2897_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","volume":"231","author":"RP DeMatteo","year":"2000","unstructured":"DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51\u20138.","journal-title":"Ann Surg"},{"key":"2897_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/cncr.23199","volume":"112","author":"RP Dematteo","year":"2008","unstructured":"Dematteo RP, Gold JS, Saran L, Gonen M, Liau KH, Maki RG, Singer S, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608\u201315.","journal-title":"Cancer"},{"key":"2897_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/SLA.0000000000003277","volume":"273","author":"MJ Cavnar","year":"2021","unstructured":"Cavnar MJ, Seier K, Curtin C, Balachandran VP, Coit DG, Yoon SS, Crago AM, et al. Outcome of 1000 patients with gastrointestinal stromal tumor (GIST) treated by surgery in the pre- and post-imatinib eras. Ann Surg. 2021;273:128\u201338.","journal-title":"Ann Surg"},{"key":"2897_CR26","first-page":"219","volume":"86","author":"G Belfiori","year":"2015","unstructured":"Belfiori G, Sartelli M, Cardinali L, Trana C, Bracci R, Gesuita R, Marmorale C. Risk stratification systems for surgically treated localized primary Gastrointestinal Stromal Tumors (GIST). Review of literature and comparison of the three prognostic criteria: MSKCC Nomogramm. NIH-Fletcher and AFIP-Miettinen Ann Ital Chir. 2015;86:219\u201327.","journal-title":"NIH-Fletcher and AFIP-Miettinen. Ann Ital Chir"},{"key":"2897_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.29271\/jcpsp.2022.01.81","volume":"32","author":"E Yuce","year":"2022","unstructured":"Yuce E, Alandag C, Cakir E, Fidan E. Prognostic factors in gastrointestinal stromal tumors (GIST): could prognostic nutritional index (PNI) be a new prognostic factor? J Coll Physicians Surg Pak. 2022;32:81\u20135.","journal-title":"J Coll Physicians Surg Pak"},{"key":"2897_CR28","doi-asserted-by":"publisher","first-page":"e7911","DOI":"10.1097\/MD.0000000000007911","volume":"96","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Hu W, Chen P, Abe M, Shi L, Tan SY, Li Y, et al. Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e7911.","journal-title":"Medicine (Baltimore)"},{"key":"2897_CR29","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1002\/cam4.1737","volume":"7","author":"H Li","year":"2018","unstructured":"Li H, Ren G, Cai R, Chen J, Wu X, Zhao J. A correlation research of Ki67 index, CT features, and risk stratification in gastrointestinal stromal tumor. Cancer Med. 2018;7:4467\u201374.","journal-title":"Cancer Med"},{"key":"2897_CR30","doi-asserted-by":"publisher","first-page":"e184060","DOI":"10.1001\/jamaoncol.2018.4060","volume":"4","author":"CP Raut","year":"2018","unstructured":"Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4:e184060.","journal-title":"JAMA Oncol"},{"key":"2897_CR31","doi-asserted-by":"publisher","first-page":"e1427","DOI":"10.1590\/0102-672020180001e1427","volume":"32","author":"J Rodrigues","year":"2019","unstructured":"Rodrigues J, Campanati RG, Nolasco F, Bernardes AM, Sanches SRA, Savassi-Rocha PR. Pre-operative gastric gist downsizing: the importance of neoadjuvant therapy. Arq Bras Cir Dig. 2019;32:e1427.","journal-title":"Arq Bras Cir Dig"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-02897-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-023-02897-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-02897-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T10:06:46Z","timestamp":1674468406000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-023-02897-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1186\/s12957-023-02897-y","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Ruijin Hospital Ethics Committee of Shanghai Jiao Tong University of Medicine<b>.<\/b>The written informed consent was obtained from all patients before enrolling in the research program.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients involved in our study provided written consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}